Defence Therapeutics Inc Class A · CSE:DTC
Defence Therapeutics Inc Class A — Investor Presentation (November 2020)
18 slides from Defence Therapeutics Inc Class A's investor presentation, November 2020
Slide 1: Corporate Deck
Corporate Deck Biopharmaceutical Innovations for Future Generations November 2020
Slide 2: Forward Looking Statements
Corporate Deck | Defence Theurapeutics Forward Looking Statements DEFENCE THERAPEUTICS This presentation contains “forward-looking information” within the meaning Defence’s short operating history; the possibility that Defence may never receive of applicable securities laws in Canada, including stat
Slide 3: Making a Global (Patient) Impact
Making a Global (Patient) Impact Defence Therapeutics are Canadian scientific pioneers on a journey to uncover enhanced treatment solutions for future generations through biopharmaceutical innovations. Leading the way with targeted science, strategic products and bold curiosity, we are uncovering mic
Slide 4: Innovative Leadership
Corporate Deck | Defence Theurapeutics Innovative Leadership LEADERSHIP SCIENCE FINANCE Dr. Moutih Rafei is an immuno-oncologist and has Joseph Meagher, CFO. (CPA, CA, C.Dir.) Sébastien Plouffe, CEO and Director. accumulated profound knowledge and insight in the Chartered Professional Accountant (CP
Slide 5: Innovative Leadership
Corporate Deck | Defence Theurapeutics Innovative Leadership SCIENCE SCIENCE Simon Beaudoin, CTSO Dr. Jeff Leyton has a BSc in biochemistry and a PhD in Molecular and Simon has a MSc and PhD in Biochemistry from the University of Medical Pharmacology from the University of California. Trained as a S
Slide 6: Innovating Pathways to Success
Innovating Pathways First to develop a combined breakthrough, with Proprietary and scalable technology Problem-driven solutions confirming strong market Fully owned assets to be capitalized via global to Success precision and efficient cell nucleus drug delivery. targeted at viruses and infectious dis
Slide 7: A Scalable Model
A Scalable Model 01 02 ACCUM™ TECHNOLOGY VACCINE DEVELOPMENT 100% Owned 100% Owned ● Primary asset: Clinical research, ADC ● Virus Formulations and Product Platform, ACCUM™ Technology Discovery ● Proprietary platform technology with ● ACCUM™ enhanced infectious disease + v proven enhanced drug deliv
Slide 8: Problem Driven Solutions
8 Ineffective Treatments ● Radiation + chemotherapy can kill tumor cells but also healthy cells. ● Nuclear-targeted biopharmaceuticals struggle with molecular obstacles which has limited their possibility to become a Problem therapeutic standard for human diseases (i.e. cancer). Driven Next-Level In
Slide 9: Micro Innovations, Macro Opportunities
Corporate Deck | Defence Theurapeutics Micro Innovations, 9 SURGING DEMAND Macro Opportunities Increasing elderly population, prevalence of chronic diseases and adoption of biopharmaceuticals globally are impacting demand. The biopharmaceutical space is ripe for innovation and investment to bring ma
Slide 10: Global Market Pioneers
Corporate Deck | Defence Theurapeutics 13.8% CAGR from 2018 to 2025 vs. $526 Global Market 3-6% for the global pharmaceuticals Billion Pioneers THE GLOBAL MARKET This indicates biopharmaceuticals are At 17% of the global destined to dominate the pharmaceutical market, overall pharmaceutical market i
Slide 11: Success Pathway: State of the Art Facilities
Corporate Deck | Defence Theurapeutics 01 Success Pathway State of the Art Facilities University of Sherbrooke laboratory is a space of 78 m2, with a 40 m2 cell culture room accommodating 10 researchers. It is equipped with ultracentrifuges, reagents, and consumables. ACCUM™ Technology provides drug
Slide 12: Success Pathways: Technology
Corporate Deck | Defence Theurapeutics 01 Success Pathways Technology Turning ADC challenges into proven platform solutions Potential Significance of Accum™ Technology ACCUM™ Talk-Worthy Results ACCUM™ Innovative Approach Overcoming problematic cell recycling 1 Antibody retains tumor cells CURRENT PO
Slide 13: Success Pathways: Highlights & Next Steps
Corporate Deck | Defence Theurapeutics 01 Success Pathways Highlights & Next Steps ● Completed pilots have proven Accum™ to be very stable, enabling higher drug retention, killing the infectious cell line by +2000x over comparable (approved) ADC, “T-DM1”. ● Recent mice trials have proven the ability
Slide 14: Accelerated Vaccine Development: COVID-19 + Cancer
Corporate Deck | Defence Theurapeutics 02 Success Pathway State of the Art Facilities University of Montreal laboratory space of 140 m2, accommodating 12 highly qualified Accelerated Vaccine Development: personnel and a wide range of equipment. COVID-19 + Cancer Access in process to 12 high tech plat
Slide 15: Success Pathways: Advanced Vaccines
Corporate Deck | Defence Theurapeutics 02 QUANTIFICATION FOR IFN-GAMMA PRODUCTION BY Success Pathways RESPONDING T CELLS (IN VITRO ANTIGEN-PRESENTING ASSAY) Advanced Vaccines 2000 1500 IFN-gamma (pg/ml) Benefiting from the multiplier ability of Accum™ (100x), 12.64x Defence Therapeutics can easily di
Slide 16: Comparables
Comparables Corporate Deck | Defence Theurapeutics BioNTech SE - ADR 84.81 USD OCT. 29 NASDAQ: BNTX +7.27 (9.38%) 2020 $21bn Gilead acquisition, effective Oct. 2020 Leader in next-generation antibody-drug conjugate $979.5m (ADC) technology, Assets as of Aug. 2020 ADC Therapeutics Sa 29.00 USD Mersan
Slide 17: Pipeline Key Milestones
Pipeline Corporate Deck | Defence Theurapeutics Key Milestones Target outcomes 2020 2021 2022 Accum™ stabilizes ADCs with no occurring off-target problems Q4 Q1 Q2 Q3 Q4 Q1 Q2 Increased accumulation equates Demonstrate Accum™ technology-driven Showcase improved tumor killing by applying Accum™ ADCs
Slide 18: Connect
Connect (514) 947 - 2272 [email protected] www.defencetherapeutics.com 1680 - 200 Burrard Street, Vancouver, BC, V6C 3L6
Defence Therapeutics — Investor Presentation (November 2020) on 6ix